Healthcare
Live Price
Offline$52.91
-0.55% today
1Y Change
+66.40%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xenon Pharmaceuticals Inc. (XENE) is a Healthcare stock with a market cap of $4.53B and listed on NASDAQ. The stock last traded around $52.91 and up 66.4% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -44.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -44.9%, free cash flow -51.7% with operating margin -4974.3% and ROIC -39.6%. Valuation already assumes a fairly strong business story at price/sales 604.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XENE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XENE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XENE Max Drawdown
-18.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XENE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$18.4M
+95.4% YoY
FY Net Income
-$78.9M
+37.1% YoY
Free Cash Flow
-$71.6M
+29.4% YoY
Revenue Growth
+0.0%
EPS Growth
-44.9%
Gross Margin
-944.0%
Net Margin
-4612.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 8M | 0 | 0 | 9M | 18M |
| Gross Profit | 5M | -3M | -168M | 9M | 18M |
| Operating Income | -373M | -279M | -214M | -129M | -79M |
| EBITDA | -342M | -236M | -211M | -128M | -78M |
| Net Income | -346M | -234M | -182M | -125M | -79M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 199M | 143M | 149M | 57M | 176M |
| Total Assets | 982M | 798M | 965M | 754M | 572M |
| Total Liabilities | 400M | 43M | 37M | 33M | 22M |
| Shareholder Equity | 582M | 755M | 928M | 721M | 550M |
| Total Debt | 8M | 9M | 11M | 10M | 8M |
| Net Debt | -191M | -134M | -138M | -47M | -167M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
70M
+29.4% YoY
Capital Expenditures
2M
+29.2% YoY
Free Cash Flow
72M
+29.4% YoY
Key ratios
Gross Margin
-944.0%
Operating Margin
-4974.3%
Net Margin
-4612.1%
ROE
-55.8%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.